Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of DepoMed (NASDAQ:ASRT), a specialty pharmaceutical company focused on developing therapies to treat central nervous system disorders, popped by as much as 13% after announcing plans to acquire migraine medicine Cambia from Nautilus Neurosciences.
So what: Under the terms of the deal, DepoMed will pay Nautilus $48.7 million to acquire the U.S. rights to the drug and could be on the line for an addition $5 million based on whether annual net sales milestones are met. According to DepoMed's press release, Cambia is the only non-steroidal anti-inflammatory drug approved for the indication of treating migraines, with drug itself seeing revenue grow in excess of 30% last quarter.
Now what: It's not often that Wall Street rewards an acquisition, but the move by DepoMed to add a rapidly growing drug that'll be protected from generic competition for another 10 years to its product portfolio appears to make a lot of sense. The next step, obviously, is to see DepoMed make strides toward turning a profit in 2014. Until I see that black ink, though, I'd rather just be a casual observer from the sidelines.